BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2023 7:39:26 AM | Browse: 126 | Download: 177
 |
Received |
|
2023-04-30 15:04 |
|
Peer-Review Started |
|
2023-04-30 15:06 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-06-07 22:22 |
|
Revised |
|
2023-06-18 20:40 |
|
Second Decision |
|
2023-08-07 02:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-08-07 08:22 |
|
Articles in Press |
|
2023-08-07 08:22 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-08-17 00:11 |
|
Publish the Manuscript Online |
|
2023-08-22 07:39 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jasmine Tidwell, Natalie Balassiano, Anjiya Shaikh and Mahmoud Nassar |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mahmoud Nassar, MD, MSc, PhD, Doctor, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, WNY 705 Maple Road, Williamsville, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu |
| Key Words |
Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Cyclophilin inhibitors; Fibroblast growth factor 21 analogs; Dual peroxisome proliferator-activated receptor agonists; Pan peroxisome proliferator-activated receptor agonists |
| Core Tip |
Non-alcoholic fatty liver disease (NAFLD) has become a significant global health issue. There is no medication approved by the Federal Drug Administration for the treatment of NAFLD. However, there are several therapeutic classes currently being studied in clinical trials. In this systematic review, we analyze the scientific data of cyclophilin inhibitors, fibroblast growth factor 21 analogs, and dual and pan peroxisome proliferator-activated receptor agonists for the treatment of NAFLD. |
| Publish Date |
2023-08-22 07:39 |
| Citation |
Tidwell J, Balassiano N, Shaikh A, Nassar M. Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review. World J Hepatol 2023; 15(8): 1001-1012 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i8/1001.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i8.1001 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
